PACS Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PACS research report →
Range $60 – $62
Price Chart
About the company
PACS Group, Inc. operates as a holding company, primarily focused on delivering post-acute healthcare services. This encompasses operating various facilities, providing skilled professionals, and offering essential ancillary support.
- CEO
- Jason Murray
- IPO
- 2024
- Employees
- 47,455
- HQ
- Salt Lake City, UT, US
Get TickerSpark's AI analysis on PACS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.93B
- P/E
- 27.74
- Fwd P/E
- 17.91
- PEG
- 0.45
- P/S
- 1.35
- P/B
- 6.33
- EV/EBITDA
- 22.18
- Div Yield
- 0.00%
- Gross Margin
- 15.67%
- Op Margin
- 7.43%
- Net Margin
- 4.87%
- ROE
- 25.77%
- ROIC
- 5.98%
Latest fiscal year · YoY change
- Revenue
- $5.29B+29.3%
- Gross Profit
- $1.16B+46.2%
- Op Income
- $309.60M
- Net Income
- $191.54M+243.5%
- EPS
- $1.23+223.7%
- OCF Growth
- +10.0%
- FCF Growth
- +1604.4%
- 52W High
- $51.68
- 52W Low
- $24.61
- 50D MA
- $45.45
- 200D MA
- $40.58
- Beta
- -0.08
- RSI (14)
- 37
- Avg Volume
- 804.92K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
PACS reported a strong Q2 with revenue, profit and margin expansion, then raised full-year guidance on the back of occupancy gains, improving mix and acquisition contributions.· August 5, 2026
- Q2 revenue rose 9.1% year over year to $1.43 billion, adjusted EBITDA increased 25% to $166.8 million, and adjusted EBITDA margin expanded 150 bps to 11.7%.
- Adjusted EPS was $0.63 versus $0.47 last year, while net income climbed 50% to $76.4 million.
- Same-store skilled nursing revenue grew 5.8% to $1.35 billion; same-store occupancy improved to 90.6% from 89.1%, and skilled mix increased to 29.7%.
- The company raised 2026 revenue guidance to $5.75 billion-$5.85 billion and adjusted EBITDA guidance to $640 million-$660 million.
- Management pointed to quality metrics, labor improvement and acquisition activity as supports, while government investigations and internal control remediation remain ongoing.
For Q2 2026, PACS reported revenue of $1.43 billion, up $118.8 million or 9.1% year over year; net income of $76.4 million, up 50%; adjusted EBITDA of $166.8 million, up 25%; and adjusted EBITDAR of $261.5 million. Adjusted EBITDA margin expanded to 11.7% from 10.2%, adjusted EPS rose to $0.63 from $0.47, and adjusted net income increased 29.6%. Same-store skilled nursing revenue increased 5.8% to $1.35 billion, same-store occupancy was 90.6% versus 89.1%, and same-store skilled mix was 29.7% versus 29.2%. For full-year 2026, revenue guidance was raised to $5.75 billion-$5.85 billion and adjusted EBITDA guidance to $640 million-$660 million; the midpoint implies 10% revenue growth and 29% adjusted EBITDA growth versus 2025. Guidance includes a modest contribution from the 20 Texas Eduro facilities closed on August 1, but excludes the remaining 14 pending facilities and other future acquisitions.
Jason Murray framed the quarter as evidence that PACS' operating model is working across its existing portfolio and that growth is translating into margin improvement as facilities mature, occupancy rises and patient mix strengthens. He emphasized quality as a core driver of payer relationships and admissions, highlighted the turnaround of a California Special Focus Facility as proof the model can improve difficult assets, and said the company is returning to a more active acquisition phase. His tone was confident and constructive, while noting that government investigations continue and remain unresolved.
Carey Hendrickson said the quarter showed continued operational improvement, with revenue growth outpacing expense growth due to occupancy gains, favorable mix and disciplined cost control. He cited $1.43 billion of revenue, $76.4 million of net income, $166.8 million of adjusted EBITDA, $261.5 million of adjusted EBITDAR and a 150 bps margin expansion to 11.7%; adjusted EPS was $0.63. On the balance sheet, PACS generated $371.8 million of operating cash flow in the first six months, had $756.6 million of available liquidity including $164.5 million of cash, had nothing drawn on its $600 million revolver, and ended with net leverage of 0.1x. He also said material weakness remediation is progressing and is expected to be completed by year-end.
Analysts focused on what is driving the raised guidance, especially stronger core trends, ramping facility improvement and the contribution from the Eduro acquisition. Management said the outlook reflects first-half strength in occupancy, skilled mix, quality and cash flow, but remains disciplined and only includes a modest contribution from the 20 Texas facilities already closed. Questions also centered on payer dynamics, Medicaid and managed care rates, with management saying quality and density are increasingly important in negotiations and that state Medicaid rate growth has been encouraging. On labor and AI, management said labor conditions have improved, contract labor in Q2 was the lowest in two years, and AI is being used to improve efficiency and documentation while keeping compliance controls tight.
The company showed broad-based operating momentum: same-store growth, occupancy gains, higher skilled mix and margin expansion all moved in the right direction. Management also described a robust acquisition pipeline, favorable labor trends and ongoing opportunities from facilities moving from new to ramping to mature, with additional upside from pending supplemental payments and future deal closings.
PACS still faces unresolved government investigations and has not given a timetable for resolution. The company also continues to work through internal control material weaknesses and integration risk from acquisitions, including the remaining Eduro facilities, with management acknowledging that guidance excludes pending transactions and that some second-half execution and integration considerations remain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 31.6%
- Shares Outstanding
- 158.72M
- Float Shares
- 50.15M
of shares held by institutions
251 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cohen & Steers, Inc. | 8.34M | ▼ 779.75K |
| Fmr LLC | 6.06M | ▼ 150.06K |
| Vanguard Group Inc | 4.51M | ▲ 566.50K |
| Blackrock, Inc. | 3.85M | ▼ 302.42K |
| Crewe Advisors LLC | 3.31M | ▲ 553.01K |
| American Century Companies Inc | 2.92M | ▼ 189.52K |
| Vanguard Portfolio Management LLC | 2.26M | ▲ 275.71K |
| Vanguard Capital Management LLC | 2.13M | ▲ 287.70K |
| Ameriprise Financial Inc | 2.00M | ▲ 873.73K |
| Dimensional Fund Advisors LP | 1.54M | ▲ 311.44K |
| Alyeska Investment Group, L.P. | 1.54M | ▼ 1.46M |
| Geode Capital Management, LLC | 1.22M | ▲ 8.84K |
Held by 373 ETFs
Biggest fund positions in PACS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Jergensen Joshua | sell | 7,283 |
| Nov 11, 26 | Jergensen Joshua | sell | 30,577 |
| Nov 11, 26 | Jergensen Joshua | sell | 2,140 |
| Nov 5, 26 | Murray Jason Hulse | sell | 17,822 |
| Nov 5, 26 | Murray Jason Hulse | sell | 1,413 |
| Nov 4, 26 | Lewis Michelle Renee | sell | 3,172 |
| Nov 2, 26 | Murray Jason Hulse | sell | 29,112 |
| Nov 2, 26 | Murray Jason Hulse | sell | 1,867 |
| Nov 2, 26 | Murray Jason Hulse | sell | 379 |
| Nov 3, 26 | Murray Jason Hulse | sell | 5,080 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PACS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on PACS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
PACS Group, Inc. to Present at the Stephens Annual Investment Conference on November 19, 2026
businesswire.com · Nov 16
3 Healthcare REITs Are Cashing In on America’s Aging Population
247wallst.com · Nov 16
Did PACS Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
prnewswire.com · Nov 12
Fifty-Eight PACS Post-Acute Locations Named Top Nursing Homes for 2027 by U.S. News & World Report
businesswire.com · Nov 10
What PACS Group (PACS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 7
Insider Selling: PACS Group (NYSE:PACS) CEO Sells $8,411,884.16 in Stock
defenseworld.net · Nov 7
PACS Group (NYSE:PACS) CEO Sells $1,443,095.16 in Stock
defenseworld.net · Nov 7
PACS Group (NYSE:PACS) CEO Sells $1,443,095.16 in Stock
defenseworld.net · Nov 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
